A Conversation with Dr. Lori Beason-Held
Tuesday, June 18, 2019
Expert estimates suggest that more than 5.5 million Americans may have dementia caused by Alzheimer’s, a disease currently ranked as the sixth-leading cause of death in the United States. Because of the condition’s growing prevalence and profound consequences for patients, understanding Alzheimer’s disease and other forms of cognitive decline is an important goal within the Intramural Research Program.
One example of the IRP’s many contributions to the field of Alzheimer’s research is a 2013 study that detected brain changes in older adults who would go on to develop cognitive impairment years before their memory began to fail. This research, led by IRP staff scientist Lori Beason-Held, Ph.D., aimed to understand who might be susceptible to developing Alzheimer’s disease and what factors contribute to the development of the disease before symptoms appear.
Tuesday, March 27, 2018
Like a bear leaves its ominous footprints in the snow, diseases and other biological processes often leave traces throughout our bodies. Recent technological and scientific advances have enabled clinicians to use measurements of these ‘biomarkers’ in their attempts to improve our health. A new study by IRP researchers revealed that patients with a sleep disorder called obstructive sleep apnea (OSA) have higher blood concentrations of certain biomarkers that may foreshadow poor brain health later in life.1
When people with OSA sleep, their throat muscles relax and block their windpipes, preventing proper breathing and often waking them up. As a result, these individuals get lower-quality sleep and their brains receive less oxygen at night.
“The overall idea is that those two conditions are not good for brain health, but nobody had really looked to see if some of the biomarkers we see in brain injury are also common in younger individuals with this type of disordered breathing,” says IRP Lasker Clinical Research Scholar Jessica Gill, Ph.D., R.N., the study’s senior author.
Thursday, September 29, 2016
What if we could diagnose risk for Alzheimer’s before symptoms appeared? To address the challenge, in the Laboratory of Neurosciences at the IRP, Dr. Maja Mustapic searches for Alzheimer’s biomarkers using liquid biopsies.